Responsible for assay development of the ever-growing clinically relevant applications within human genetics and infectious diseases markets for screening, diagnosis and monitoring, using Bio-Rad's digital droplet PCR technology. Successfully launched SARS-CoV-2 ddPCR Kit which was granted Emergency Use Authorization by FDA on 05/01/2020.

• Lifecycle core team member, represent project teams from early concept/project initiation to product launch, stakeholder in business roadmap and portfolio strategy• Accountable for the outcome of all the projects in the Product Development portfolio • Leading the development of Class III assays for registration in the US, EU and China• Demonstrated ability to deliver high quality IVD milestones and products (assays and result-in, report out end-to-end solutions) on time and on budget

• Development Lead for the Virology (HIV, HCV, HBV) and Hereditary Oncology programs, responsible for budgeting, resourcing, planning and oversight of product development activities: end-to-end assay workflow comprising nucleic acid extraction, target enrichment, library preparation, next generation sequencing and bioinformatics pipeline• Responsible for the functional management of a team of 11 scientists from diverse backgrounds and subject matter expertise areas • Stakeholder providing key input for the company’s market strategy in a cross-functional effort to determine 5 and 10 year assay roadmap • Next-generation sequencing subject-matter expert (Illumina, Ion Torrent, Pacific Biosciences’s SMRT, and Roche’s Nanopore sequencing technologies)

• Promoted into new role as Development Lead and functional manager for the Cytology group, a newly created team within the organization• Successful launch of CINtec PLUS Cytology, the first assay of its kind at RTD and an integral product for the Roche Cervical Cancer portfolio• Responsible for scientific research, feasibility, verification and validation activities, and manufacturing assay transfer of the projects in development• RTD Development representative for Chief Technical Officer (CTO) due diligence reviews

- Technical lead for the development and launch of three Class I/CE-IVD primary antibodies- Team member involved in planning pre-market approval strategies of assays in development- Experienced in immunohistochemistry and immunocytochemistry techniques

- Focused on product improvement and on-market support- Technical lead of four CAPA projects that met their objectives on time and on budget, resulting in improved customer satisfaction and reagent compliance

- Research focused on stem cells involved in bone health and the mechanisms that drive malignant and non-malignant skeletal pain, in order to develop clinically relevant models. - Leader of research sub-team with emphasis on tracking neurochemical responses to skeletal pain via fluorescent IHC and micro-computerized tomography- Moved from MN to AZ and successfully set up a state-of-the-art laboratory in 2 months - Responsible for experimental design and execution, quantification, interpretation and presentation of scientific results- Involved in manuscript and grant preparation and submission process

- Research focused on stem cells involved in bone health and the mechanisms that drive malignant and non-malignant skeletal pain, in order to develop clinically relevant models. - Leader of research sub-team with emphasis on tracking neurochemical responses to skeletal pain via fluorescent IHC and micro-computerized tomography- Moved from MN to AZ and successfully set up a state-of-the-art laboratory in 2 months - Responsible for experimental design and execution, quantification, interpretation and presentation of scientific results- Involved in manuscript and grant preparation and submission process